





RECEIVED

OCT 3 1 2002

TECH CENTER 1600/2900

Fulbright & Jaworski L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE, SUITE 2400 AUSTIN, TEXAS 78701-3271 WWW.FULBRIGHT.COM

SHIGHLANDER@FULBRIGHT.COM

PARTNER

DIRECT DIAL: (512) 536-3184

TELEPHONE: FACSIMILE:

(512) 474-5201

(512) 536-4598

October 23, 2002

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

> October 23, 2002 Date

dighlander

Commissioner for Patents Washington, DC 20231

Re:

U.S. Serial No. 09/899.376 Entitled: "ISOLATION OF A CELL-SPECIFIC INTERNALIZING PEPTIDE THAT INFILTRATES TUMOR TISSUE FOR TARGETED DRUG DELIVERY" by Frank D. Hong and Gary Clayman

(Client Ref. MDA00-009)

Matter No. 10105754/UTSC:645US

Enclosed for filing in the above-referenced patent application is:

- 1. Response to Restriction Requirement Dated September 23, 2002; and
- 2. A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

If the check is inadvertently omitted, or the amount is insufficient, or should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, or should an overpayment be included herein, the Commissioner is authorized to deduct or credit said fees from or to Fulbright & Jaworski L.L.P. Account No.: 50-1212/10105754/SLH.

lly yours,

Steven L. Highlander

SLH/cpj

Encl: As noted

25223994.1





TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

October 23, 2002

Date

Steven A. Highlander

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Frank D. Hong and Gary Clayman

Serial No.: 09/899,376

Filed: July 2, 2001

For: ISOLATION OF A CELL-SPECIFIC

INTERNALIZING PEPTIDE THAT INFILTRATES TUMOR TISSUE FOR

TARGETED DRUG DELIVERY

Group Art Unit:

1642

Examiner:

Christopher H. Yaen

Atty. Dkt. No.:

UTSC:645US/SLH

RESPONSE TO RESTRICTION REQUIREMENT DATED SEPTEMBER 23, 2002

Commissioner for Patents Washington, D.C. 20231

Sir:

This paper is submitted in response to the Restriction Requirement dated September 23, 2002 for which the date for response is October 23, 2002. No fees are believed due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct or credit said fees from or to Fulbright & Jaworski Deposit Account No. 50-1212/10105754/SLH.

In response to the restriction requirement which the Examiner imposed, Applicants elect, without traverse, to prosecute claims 1-3 and 7-15, *i.e.*, the Group I claims.

The Examiner is invited to contact the undersigned attorney at (512) 536-3184 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,

Steven D. Highlander Reg. No. 37,642

Attorney for Applicants

FULBRIGHT & JAWORSKI 600 Congress Avenue Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

October 23, 2002